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Abstract  Barrett’s  esophagus  is  a  premalignant  condition  of  the  esophagus  in  which  the  squa-
mous epithelium  of  the  lower  end  of  the  esophagus  is  replaced  with  columnar  epithelium.  Since
the incidence  of  esophageal  adenocarcinoma  is  on  the  rise,  the  major  gastroenterology  soci-
eties have  come  up  with  their  recommendations  for  screening  and  surveillance.  Speciﬁc  factors
like obesity,  white  race,  age  over  50  years,  early  age  of  onset  of  GERD,  smoking  and  hiatal
hernia have  been  identiﬁed  as  increasing  the  risk  of  Barrett’s  esophagus  and  adenocarcinoma.
The diagnosis  requires  both  endoscopic  identiﬁcation  of  columnar-lined  mucosa  and  histolog-
ical conﬁrmation  with  biopsy.  Most  medical  societies  recommend  screening  people  with  GERD
and other  risk  factors  with  endoscopy,  but  other  alternatives  employing  less  invasive  methods
are currently  being  studied.  Surveillance  strategies  vary  depending  on  the  endoscopic  ﬁndings
and the  Seattle  biopsy  protocol  with  random  4-quadrant  sampling  is  recommended.  Biomarkers
have shown  promising  results,  but  more  studies  are  needed  in  the  future.  White  light  endoscopy
is the  standard  practice,  but  other  advanced  imaging  modalities  have  shown  variable  results
and hence  more  studies  are  awaited  for  further  validation.  Endoscopic  eradication  techniques,
including  both  resection  and  ablation,  have  shown  good  but  variable  results  for  treating  dysplas-
tic lesions  conﬁned  to  the  mucosa.  Resection  procedures  to  remove  visible  lesions  followed  by
ablation of  the  dysplastic  mucosa  have  shown  the  best  results  with  higher  eradication  rates  and
lower recurrence  rates.  Surgical  management  is  reserved  for  lesions  with  sub-mucosal  invasion
and lymph  node  spread  with  increased  risk  of  metastasis.
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Manejo  del  esófago  de  Barrett:  del  tamizaje  a  los  nuevos  tratamientos
Resumen  El  esófago  de  Barrett  es  un  trastorno  premaligno  del  esófago  en  el  cual  el  epitelio
escamoso de  la  porción  distal  del  esófago  es  reemplazado  por  epitelio  columnar.  Debido  a  que
la incidencia  de  adenocarcinoma  esofágico  se  encuentra  al  alza,  la  mayoría  de  las  sociedades
de Gastroenterología  han  emitido  sus  propias  recomendaciones  para  el  tamizaje  y  la  vigilancia.
Factores especíﬁcos  como  la  obesidad,  la  raza  blanca,  la  edad  por  encima  de  los  50  an˜os,  el
inicio del  ERGE  a  edad  temprana,  el  tabaquismo  y  la  hernia  hiatal  han  sido  identiﬁcados  como
factores que  incrementan  el  riesgo  de  esófago  de  Barrett  y  adenocarcinoma.  El  diagnóstico
requiere  tanto  de  la  identiﬁcación  endoscópica  de  mucosa  con  revestimiento  columnar  como
de la  conﬁrmación  histológica  con  biopsia.  La  mayoría  de  las  sociedades  médicas  recomiendan
tamizar a  todas  las  personas  con  ERGE,  así  como  aquellos  con  otros  factores  de  riesgo  con
endoscopia;  sin  embargo,  otras  alternativas  que  utilizan  métodos  menos  invasivos  se  encuen-
tran bajo  estudio  en  la  actualidad.  Las  estrategias  de  vigilancia  varían  dependiendo  de  los
hallazgos endoscópicos  y  se  recomienda  el  protocolo  de  biopsias  de  Seattle  con  un  muestreo
de 4  cuadrantes  aleatorizado.  Algunos  biomarcadores  han  mostrado  resultados  prometedores,
aunque se  requieren  de  más  estudios  en  el  futuro.  La  endoscopia  de  luz  blanca  es  el  estándar  en
la práctica,  sin  embargo,  otras  modalidades  de  imagen  más  avanzadas  han  mostrado  resultados
variables  y,  por  lo  tanto,  se  esperan  más  estudios  para  obtener  validación  adicional.  Las  técni-
cas de  erradicación  endoscópica,  incluyendo  tanto  la  resección  como  la  ablación,  han  mostrado
buenos resultados,  aunque  variables,  en  el  tratamiento  de  lesiones  displásicas  conﬁnadas  a
la mucosa.  Los  procedimientos  de  resección  para  remover  las  lesiones  visibles  seguida  por  la
ablación de  la  mucosa  displásica  han  mostrado  los  mejores  resultados,  con  tasas  de  erradicación
más altas  y  menores  tasas  de  recurrencia.  El  manejo  quirúrgico  está  reservado  para  lesiones
con invasión  de  la  submucosa  y  propagación  a  ganglios  linfáticos  con  un  riesgo  incrementado
de metástasis.
© 2016  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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arrett’s  esophagus  (BE)  is  a  pre-malignant  condition  of  the
sophagus  in  which  the  squamous  epithelium  of  the  lower
nd  of  the  esophagus  is  replaced  with  columnar  epithelium.
t  is  generally  due  to  chronic  mucosal  damage  caused  by
astroesophageal  reﬂux  disease  (GERD).  The  incidence  of  BE
n  the  United  States  has  been  estimated  at  about  5.6%  of  the
eneral  population.1 In  recent  years,  BE  has  become  a focus
f  studies  as  the  incidence  of  esophageal  adenocarcinoma
EAC)  is  on  the  rise  in  the  western  world  and  is  currently
he  ﬁfth  leading  cause  of  cancer-related  deaths  among  men
orldwide.2 The  sequence  of  GERD  leading  to  BE,  which  is
remalignant  and  eventually  leads  to  EAC,  has  gained  the
ttention  of  physicians  around  the  world,  resulting  in  the
laboration  of  guidelines  for  screening  and  surveillance.
pidemiology
he  prevalence  of  BE  has  been  difﬁcult  to  estimate,  as  most
f  the  patients  are  asymptomatic  and  remain  undiagnosed.
arious  rates  have  been  reported  from  different  parts  of
he  world.  In  a  prospective  study  reported  by  Rex  et  al.
ased  on  upper  endoscopy  (EGD)  offered  to  patients  under-
oing  colonoscopy,  the  prevalence  of  BE  was  6.8%  with  a
hort-segment  BE  rate  of  5.5%.3 A  similar  study  with  a
o
t
v
imaller  cohort  conducted  by  Ward  et  al.  revealed  short-
egment  BE  in  15%  and  long-segment  Barrett’s  esophagus
n  4%,  but  this  cohort  had  a  signiﬁcantly  older  population.4
onkainen  et  al.  published  a  study  from  Sweden  based  on
GD  done  on  1,000  random  individuals  and  reported  a  preva-
ence  of  BE  of  1.6%  with  a  short-segment  BE  of  1.1%  and
 long-segment  BE  of  0.5%.5 Zagari  et  al.  from  Italy  pub-
ished  a  study  with  BE  prevalence  of  1.3%  and  long-segment
E  of  0.2%,6 whereas  Zou  et  al.  from  China  reported  BE  of
.9%  and  long-segment  BE  of  0.5%.7 Published  studies  have
eported  an  increasing  incidence  and  prevalence  of  BE  in
he  male  population  with  a  ratio  of  almost  2:1,  also  asso-
iated  with  earlier  presentation  in  males  than  in  females.8
his  may  partly  be  due  to  the  protective  effect  of  estro-
ens  in  females,9 which  may  be  lost  as  they  age,  and  to  the
evelopment  of  obesity,  leading  to  reﬂux  esophagitis10 and
onsequent  BE.
There  are  several  other  risk  factors  for  BE  and  EAC  which
ave  been  identiﬁed  in  clinical  studies.  Obesity,  white  race,
lder  age,  chronic  heartburn,  early  age  of  onset  of  GERD,
iatal  hernia,  smoking,  a  family  history  of  GERD  or  familial
orms  of  Barrett’s  esophagus,  and  obstructive  sleep  apnea
ave  been  recognized  as  signiﬁcant  risk  factors.11 The  use
f  nonsteroidal  anti-inﬂammatory  drugs,  statins,  Helicobac-
er  pylori  (H.  pylori) infection  and  a  diet  rich  in  fruits  and
egetables  have  been  found  to  protect  against  BE.  H.  pylori
nfection  causes  gastritis,  which  leads  to  decreased  gastric
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ing  to  decreased  rates  of  detection.44,45 Furthermore,  it  isManagement  of  Barrett’s  esophagus:  Screening  to  newer  tre
acid  production  and  hence  decreased  acid  reﬂux,  thus  offer-
ing  a  protective  inﬂuence  against  BE.11
There  has  been  increasing  incidence  in  both  BE  and  EAC
in  the  developed  countries  in  the  past  few  decades  that
has  been  attributed  to  several  factors.  The  increasing  inci-
dence  of  obesity,  especially  truncal  obesity,  which  promotes
GERD  and  hence  carcinogenesis,  has  been  a  major  risk  fac-
tor.  It  has  been  shown  to  increase  GERD  by  1.5-2%  and  risk  of
EAC  by  2-2.5%.11 Abdominal  circumference  (waist-hip  ratio)
has  been  identiﬁed  as  an  independent  risk  factor.12 Vis-
ceral  obesity  also  leads  to  a  pro-inﬂammatory  state  with  the
increase  of  several  cytokines,  such  as  interleukins,  tumor
necrosis  factor  alpha,  C-reactive  protein,  and  leptin,  lead-
ing  to  elevated  cell  proliferation  and  reduced  apoptosis,
and  eventually  to  EAC.13,14 Decrease  in  the  incidence  of
H.  pylori  infection  in  these  countries  leading  to  increased
acid  secretion  and  GERD  has  also  been  postulated.15 Dietary
modiﬁcations  involving  more  nitrates  in  both  the  food  and
the  fertilizers  used  in  growing  them,  together  with  low  lev-
els  of  antioxidants  in  food,  could  also  be  a  contributing
factor.16
Diagnostic criteria
The  diagnosis  of  BE  requires  both  endoscopic  identiﬁcation
of  columnar-lined  mucosa  and  the  histologic  presence  of
intestinal-type  metaplasia.17 The  mucosa  of  the  esophagus
is  normally  lined  with  stratiﬁed  squamous  epithelium  and
it  changes  to  columnar  epithelium  at  the  level  of  the  gas-
troesophageal  (GE)  junction,  which  is  identiﬁed  by  the  end
of  the  proximal  gastric  mucosal  folds.  The  squamous  epithe-
lium  is  pale  and  glossy  in  architecture,  whereas  the  columnar
epithelium  is  salmon-colored.  Normally  the  squamocolum-
nar  junction  coincides  with  the  GE  junction,  but  when  it  is
proximal  to  the  GE  junction,  there  is  a  columnar  epithelium-
lined  esophagus,  which  is  considered  BE.  If  the  segment
is  <  3  cm,  it  is  called  short-segment  BE  and  if  ≥  3  cm  it  is
long-segment  BE.18 Short-segment  BE  was  not  widely  rec-
ognized  until  1994  and  earlier  studies  generally  reported
long-segment  BE.19 More  recent  studies  have  found  varying
proportions  of  both,  and  thus  they  could  inﬂuence  symptoms
and  complications.  The  endoscopic  extent  of  Barrett’s  seg-
ment  should  be  reported  using  the  Prague  criteria,  which
includes  both  the  circumferential  extent  (C)  and  the  maxi-
mum  extent  (M)  of  the  endoscopically  visible  columnar-lined
esophagus  and  separate  islands  above  the  main  segment
noted  in  centimeters  from  the  GE  junction.20 Several  soci-
eties  including  the  American  societies  require  specialized
columnar  cells  with  secretory  cells  called  goblet  cells,  oth-
erwise  known  as  intestinal  metaplasia,  to  be  present  in  the
biopsy  samples  of  the  esophagus  to  diagnose  BE.21--23 There
is  a  controversy  as  to  whether  to  accept  cardiac  type  colum-
nar  cells  (without  goblet  cells)  as  a  criterion,  but  the  British
Society  of  Gastroenterology  accepts  them  according  to  their
recently  updated  guidelines.24
ScreeningThe  traditional  strategy  has  been  to  screen  patients  with
GERD  with  an  endoscopy  and  to  identify  columnar  meta-
plastic  epithelium,  obtain  biopsy  specimens  to  conﬁrm  BE,
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dentify  dysplasia,  and  then  treat  them.  There  are  several
itfalls  associated  with  this  strategy.  Despite  the  rising  inci-
ence  of  EAC,  the  annual  cancer  incidence  of  EAC  from  BE
as  been  shown  to  be  only  0.1  to  0.3%,  which  is  still  rela-
ively  low.25--28 Nearly  40%  of  the  patients  with  EAC  have  no
rior  history  of  GERD  and  only  10%  of  the  patients  with  EAC
ave  a  prior  diagnosis  of  BE.29--31
Most  medical  societies  recommend  endoscopic  screening
n  patients  with  GERD,  along  with  other  risk  factors  for  BE,
uch  as  age  >  50  years,  male  sex,  white  race,  intra-abdominal
at  distribution  with  truncal  obesity,  tobacco  use,  elevated
ody  mass  index  (BMI),  and  hiatal  hernia.17,22,23,32
Newer  less  invasive  screening  modalities  such  as  unse-
ated  trans-nasal  endoscopy  and  video  capsule  endoscopy
ave  been  studied.  They  had  better  participation  rates  than
edated  endoscopy33 and  also  proved  to  be  cost-effective.
apsule  endoscopy  has  shown  a  high  diagnostic  yield  in  a
ew  pilot  studies,34,35 whereas  other  studies  have  reported
 low  sensitivity  and  speciﬁcity36 with  higher  cost,  making  it
 disadvantage.  The  cytosponge  test,  an  ingestible  samp-
ing  device  that  allows  cytology  samples  to  be  retrieved
rom  the  esophagus  to  run  immunohistochemical  assays  has
hown  promising  results37,38 with  reduction  in  mortality  com-
ared  with  no  screening.39 Currently  none  of  these  have
eplaced  the  traditional  endoscopy  with  sedation  due  to  lack
f  evidence  suggesting  that  they  are  superior  to  standard
creening  methods.
urveillance
he  goal  of  endoscopic  surveillance  is  to  identify  precancer-
us  lesions  at  an  early  stage  and  intervene  with  a  curative
ntent.  EAC  had  a  very  poor  survival  rate  of  only  13%  at
he  end  of  5  years.40 Patients  with  BE  were  enrolled  in
ndoscopic  surveillance  programs  and  were  risk-stratiﬁed
ased  on  the  presence  of  different  grades  of  dysplasia  after
istopathologic  study.  There  are  no  prospective  randomized
ontrolled  trials  that  demonstrate  the  efﬁcacy  and  superior-
ty  of  these  surveillance  strategies  in  identifying  the  patients
t  risk,  as  the  annual  incidence  of  EAC  is  still  low  and  a  sig-
iﬁcant  proportion  of  those  patients  do  not  have  BE.  In  a
utch  cohort  study,  only  5.6%  of  the  patients  with  BE  died
ue  to  EAC.41
The  biopsy  protocol  that  is  currently  recommended  dur-
ng  endoscopy  is  the  Seattle  protocol.  It  involves  targeted
ampling  of  the  endoscopically  visible  lesions  followed  by
andom  4-quadrant  biopsy  sampling  every  1-2  cm  starting
rom  the  proximal  gastric  folds  to  the  uppermost  part  of  the
quamocolumnar  junction.  The  biopsy  should  proceed  in  a
istal  to  proximal  fashion.  This  has  been  proven  to  increase
he  yield  with  regards  to  diagnosis  of  dysplasia  in  BE.42 Even
ith  adherence  to  this  protocol,  it  is  possible  to  sample  only
p  to  6%  of  the  BE  area.43 Studies  have  shown  that  this  rig-
rous  protocol  is  not  followed  completely  in  many  cases,
specially  in  patients  with  the  highest  risk  of  dysplasia,  lead-ifﬁcult  to  adhere  to  this  protocol  in  patients  with  small-
egment  BE.  Hence  the  need  for  better  imaging  and  visual
odalities,  as  described  below,  for  better  identiﬁcation  of
ysplasia  and  those  at  the  highest  risk  for  EAC.
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ecommendations for Screening and Surveillance for Barrett’s Esophagus from various
astro-intestinal  Societies
AGA  ASGE  ACG  BSG  SFED  ACP
riteria  for
screening
Patients
with
multiple  risk
factors  for
EAC
Patients  with
multiple  risk
factors  for  EAC
and  must  be
informed  that
evidence  is
insufﬁcient
Speciﬁc
populations  at
high  risk--has  to
be
individualized
Patients
with
multiple  risk
factors  for
EAC
Patients
with  GERD
and
depending
on  age  and
general
health
status,  if  it
would  offer
beneﬁt
Age  >  50
years,
Chronic
GERD  >  5
years  and
additional
risk  factors
for  EAC
urveillance of
NDBE
Every  3-5
years
Every  3-5  years  Every  3  years  Every  2-3
years
SSBE  5  yrs,
LSBE
(3-6cm)  3
yrs,
LSBE  >  6  cm
2 yrs
Every  3-5
years
urveillance of
LGD
Every  6-12
months
Repeat
endoscopy  in  6
months  and
then  annually
Repeat
endoscopy  in  6
months  and
then  annually
until  2
successive  no
dysplasias
Every  6
months
At  6
months,  1
year,  and
then
annually
Not
addressed
urveillance of
HGD
Every  3
months
Only  for
patients  unﬁt
for/  refusing
therapy
Every  3  months  Endoscopic
therapy
preferred
Endoscopic
or  surgical
therapy
Not
addressed
reatment of
GERD
PPI  recom-
mended
Not  addressed  PPI
recommended
PPI  recom-
mended
Double  dose
PPI:  2
months  for
LGD  and  1-2
months  for
HGD
Not
addressed
reatment of
HGD/  IMC
Endoscopic
eradication
therapy
EMR  and/or  RFA  Should  be
individualized
-- surgery  vs
endoscopic
eradication  vs
surveillance
Endoscopic
therapy
preferred
No  speciﬁc
recommen-
dations
Not
addressed
CG: American College of Gastroenterology; ACP: American College of Physicians; AGA: American Gastroenterology Association; ASGE: Amer
can Society of Gastrointestinal Endoscopy; BSG: British Society of Gastroenterology; EAC: Esophageal adenocarcinoma; EMR: Endoscopi
ucosal resection; GERD: Gastroesophageal reﬂux disease; HGD: High-grade dysplasia; IMC: Intra-mucosal carcinoma; LGD: Low-grade dys
lasia; LSBE: Long-segment Barrett’s esophagus; NDBE: Non-dysplastic Barrett’s esophagus; PPI: Proton pump inhibitor; RFA: Radiofrequenc
blation; SFED: French Society of Gastrointestinal Endoscopy; SSBE: Short-segment Barrett’s esophagus
iomarkers
isk  stratiﬁcation  for  cancer  in  patients  with  BE  is  currently
ased  on  the  presence  of  dysplasia  in  histology,  although
he  diagnosis  and  grading  of  dysplasia  are  limited  by  mod-
rate  to  poor  interobserver  agreement.  Several  biomarkers
ave  been  proposed  to  predict  the  neoplastic  progres-
Aberrant  p53  expression  was  associated  with  an  increased
risk  of  progression  to  cancer  with  overexpression  having
a  relative  risk  of  5.6  and  loss  of  expression  with  a  rela-
tive  risk  of  14.  The  positive  predictive  value  increased  from
15%  with  LGD  alone  to  33%  with  concurrent  LGD  and  aber-
rant  p53  expression.46 Other  biomarkers  like  aneuploidy/
tetraploidy,47,48 17p  loss  of  heterozygosity  (LOH),49 9p  LOH,ion  from  BE,  but  only  cross-sectional  studies  have  been
erformed  and  there  are  no  validated  prospective  trials.
mmunohistochemistry  staining  of  p53  has  been  studied
nd  proposed  as  an  adjunct  to  dysplasia  for  diagnosis.
a
i
a
pnd  gene  methylation-based  biomarkers  have  shown  promis-
ng  results.50 Current  data  suggests  that  these  biomarkers
re  no  better  than  a  histological  ﬁnding  of  high-grade  dys-
lasia  (HGD)  in  predicting  cancer  progression,  but  may  be
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superior  in  prediction  compared  with  non-dysplastic  Bar-
rett’s  esophagus  (NDBE),  indeterminate  dysplasia,  or  LGD.
The  combination  of  biomarkers  and  histology  can  provide
even  better  results.  More  studies  may  be  available  in  the
future  and  hence  these  biomarkers  can  be  used  to  predict
which  patients  would  beneﬁt  from  surveillance  vs  ablation.
Advanced imaging modalities
Apart  from  high  resolution  white  light  endoscopy,  other
advanced  techniques,  such  as  narrow  band  imaging  (NBI),
chromo-endoscopy,  autoﬂuorescence  imaging  (AFI),  confo-
cal  laser  micro-endoscopy,  diffuse  reﬂectance  spectroscopy,
light  scattering  spectroscopy,  and  optical  coherence  tomo-
graphy  (OCT)  have  recently  emerged.  Currently  white  light
inspection  of  the  esophagus  using  high  resolution  endoscopy
is  the  standard  of  practice  and  guidelines  do  not  recom-
mend  routine  use  of  advanced  endoscopic  imaging  either
for  screening  or  surveillance  of  patients  with  BE.  With
the  advances  in  technology,  combining  normal  white  light
endoscopy  with  magniﬁcation  devices  and  high  resolution
television  systems  has  enabled  the  production  of  higher
quality  images  that  have  been  shown  to  have  a  higher  sen-
sitivity  for  the  detection  of  dysplasia  and  early  neoplastic
lesions  in  BE.51,52
Virtual  chromo-endoscopy  involves  the  application  of
chemical  agents  and  dyes  that  highlight  speciﬁc  areas  of  the
esophageal  mucosa  and  therefore  aid  in  targeted  biopsies.
Several  agents,  such  as  methylene  blue,  Lugol’s  iodine  solu-
tion,  indigo  carmine  dye,  and  acetic  acid  have  been  used
for  this  purpose.  Lugol’s  iodine  stains  the  squamous  cells
of  the  epithelium  which  contains  glycogen  and  thus  enables
the  identiﬁcation  of  Barrett’s  islands  with  columnar  mucosa
after  eradication  therapy  for  BE.53 The  studies  using  methy-
lene  blue  to  stain  the  non-dysplastic  areas  in  the  BE  have
reported  mixed  results.  Horwhat  et  al.  conducted  a  ran-
domized,  prospective,  cross-over  trial  in  48  patients  and
demonstrated  that  the  yield  of  detecting  BE  or  dysplasia
was  similar  among  patients  who  received  targeted  biopsies
using  methylene  blue  and  in  those  patients  who  had  random
4-quadrant  biopsies,  but  required  signiﬁcantly  fewer  biop-
sies  compared  with  random  4-quadrant  biopsies  (9.23  ±  2.89
and  18.92  ±  6.36,  respectively)  (p  <  0.001).54 Lim  et  al.  con-
cluded  a  randomized  cross-over  study  with  30  patients  with
a  mean  length  of  Barrett’s  segment  of  5  cm.  Overall,  17  out
of  the  18  patients  with  dysplasia  were  identiﬁed  by  ran-
dom  4-quadrant  biopsies,  whereas  only  9  were  identiﬁed
using  methylene  blue  (p  =  0.02).55 Ngamruengphong  et  al.
conducted  a  meta-analysis  reporting  the  diagnostic  yield
of  using  methylene  blue  chromoendoscopy.  There  was  no
signiﬁcant  incremental  yield  (IY)  over  random  4-quadrant
biopsies  for  metaplasia  (IY  4%),  dysplasia  (IY  9%),  and  early
cancer  (IY  5%).56 Olliver  et  al.  claimed  that  it  could  lead  to
DNA  damage  in  Barrett’s  epithelium,  and  thus  could  poten-
tially  accelerate  carcinogenesis.57 Four  speciﬁc  pit  patterns
have  been  identiﬁed  in  studies  using  application  of  both
acetic  acid  and  indigo  carmine--round,  reticular,  ridged,  and
villous.  Guelred  et  al.  described  that  the  ridged  and  villous
patterns  were  associated  with  intestinal  metaplasia  using
acetic  acid,  whereas  another  study  used  indigo  carmine  in
80  patients  and  reported  that  the  ridged/villous  pattern
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ad  a  sensitivity  of  97%  and  speciﬁcity  of  76%  for  intestinal
etaplasia.53
NBI  is  a form  of  electronic  chromo-endoscopy  that  uses
pectral  narrow  band  optical  ﬁlters,  optical  band  imaging,
nd  I-scan  to  highlight  the  vascular  patterns  or  to  dif-
erentiate  the  contrast  between  squamous  and  columnar
pithelium.58 Prospective  trials  comparing  NBI  with  high  res-
lution  white  light  endoscopy  have  been  published.  In  the
tudy  conducted  by  Wolfsen  et  al.  with  65  patients  known
o  have  dysplasia  in  BE,  NBI  identiﬁed  more  patients  with
ysplasia  and  also  higher  grades  of  dysplasia  compared  with
hite  light  endoscopy.59 In  another  randomized,  multicen-
er  cross-over  trial  which  compared  both,  NBI  detected  the
ame  number  of  patients  with  metaplasia,  but  a higher  pro-
ortion  of  areas  with  dysplasia  (30%  vs  21%,  p  =  0.01).60
egular-appearing  mucosa  and  vessels  with  NBI  did  not
arbor  any  high-grade  dysplasias.  Moreover,  they  required
igniﬁcantly  fewer  biopsies  than  with  white  light  endoscopy
3.6  vs.  7.6,  p  <  0.0001)
AFI  endoscopy  is  based  on  the  principle  that  when  a
aser  light  is  emitted  by  endoscopy,  cells  would  re-emit
 ﬂuorescent  light  with  distinct  spectroscopic  characteris-
ics.  Kara  et  al.  found  that  it  is  a  study  with  very  good
ensitivity  for  identifying  HGD,  but  with  poor  speciﬁcity
nd  a  high  false  positive  rate.61 Mannath  et  al.  pub-
ished  a  recent  report  studying  the  interobserver  agreement
etween  experts  and  non-experts  for  AFI.62 They  concluded
hat  there  was  fair-to-moderate  agreement  for  AFI  alone,
hich  improved  when  it  was  combined  with  high  resolu-
ion  white  light  endoscopy.  Curvers  et  al.  published  a  report
hat  utilized  a  ‘‘trimodal  imaging’’  technique  in  which  the
sophagus  was  ﬁrst  examined  using  the  normal  high  res-
lution  white  light  followed  by  AFI  to  highlight  abnormal
reas  not  seen  with  white  light,  followed  by  NBI  to  conﬁrm
he  abnormal  areas  in  AFI.63 AFI  diagnosed  a  signiﬁcantly
igher  proportion  of  abnormal  areas  than  white  light,  but
ith  a  higher  false  positive  rate  of  81%,  which  was  reduced
o  26%  with  NBI.  It  could  still  not  replace  the  traditional
-quadrant  biopsy,  as  10%  of  the  cases  were  missed  by  all
 modalities.
Confocal  micro-endoscopy  uses  the  technique  of  trans-
ation  of  reﬂected  endoscopy-derived  laser  light  onto  the
omputer  into  a cross-sectional  image  of  the  mucosal
rchitecture.  Real  time  analysis  of  the  blood  vessels  and
he  crypts  can  be  performed.  Reports  published  so  far
ave  shown  good  accuracy  rates  (85%-94%)  of  dysplasia
etection.64,65 Pohl  et  al.  conducted  a  prospective  2-center
rial  and  reported  that  the  confocal  laser  microscopy  crite-
ia  for  BE  were  more  frequently  detected  in  HGD  and  early
ancer  than  in  low-grade  dysplasia,  with  good  interobserver
greement  with  a  kappa  value  of  0.6.66 The  spectroscopic
echniques  are  based  on  the  analysis  of  the  light  scattered
rom  the  tissue.  Diffuse  reﬂectance  spectroscopy  analy-
es  the  light  scattered  multiple  times  within  the  tissue,
hereas  light  scattering  spectroscopy  uses  light  reﬂected
nly  once.  These  techniques  have  been  reported  to  dis-
inguish  higher  grades  from  lower  grades  of  dysplasia  and
lso  from  no  dysplasia  up  to  88%  with  a  sensitivity  and
peciﬁcity  approaching  90%.  OCT  uses  near-infrared  light
o  provide  high  resolution  images  and  initial  studies  have
eported  higher  sensitivity  and  speciﬁcity  rates  of  > 90%  in
he  detection  of  metaplasia.67--69
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Despite  having  promising  results,  more  studies  are
eeded  to  validate  these  techniques,  optimizing  the  associ-
ted  costs  and  developing  ideal  teaching  methods  to  get  this
echnology  to  gastroenterologists  beyond  the  tertiary  cen-
ers.  Currently  high  resolution  endoscopy  with  white  light
ith  random  4-quadrant  biopsies  has  been  the  most  widely
ccepted  modality  for  diagnosis  of  metaplasia  and  dysplasia
n  BE.
ndoscopic eradication techniques
radication  using  endoscopic  techniques  involves  either
 resection  procedure  like  endoscopic  mucosal  resection
EMR)  and  endoscopic  sub-mucosal  dissection  (ESD)  or  abla-
ive  procedures  of  the  BE  mucosa  with  several  techniques.
he  advantage  with  the  resection  procedures  is  that  they  are
oth  diagnostic  and  therapeutic  as  we  get  a  tissue  sample,
hereas  the  ablative  procedures  are  only  therapeutic.  All
ndoscopic  procedures  should  be  followed  by  acid  suppres-
ion  therapy  to  allow  for  healing  and  re-epithelialization  of
he  esophageal  mucosa  with  squamous  epithelium.
Surgical  procedures  used  to  be  the  treatment  of  choice
ven  for  early  pre-malignant  lesions,  but  endoscopic  meth-
ds,  thanks  to  the  advances  made,  are  now  being  used  more
idely.  One  important  criterion  to  be  considered  before
electing  endoscopic  therapy  is  to  assess  the  extent  of  the
nvolvement  of  dysplasia  in  BE.  It  must  be  conﬁned  only  to
he  mucosa  (T1a  stage)  and  there  should  be  no  involvement
f  the  submucosa,  in  which  case  surgical  management  is  the
tandard  of  care.  It  has  been  proven  that  early  neoplasms
nvolving  only  the  mucosa  have  a  1-2%  risk  of  lymph  node
etastasis,70 whereas  those  with  sub-mucosal  invasion  have
 10%  risk  of  lymphadenopathy,71 and  a  few  reports  have
uggested  up  to  20%.72,73 Therefore,  an  accurate  T-staging  is
ssential  before  deciding  on  therapy.  Endoscopic  ultrasound
EUS)  is  the  most  accurate  imaging  modality  for  T-staging
f  neoplasms,  but  they  can  predict  the  depth  of  invasion
n  only  50-60%  of  the  cases.  On  the  other  hand,  studies  on
MR  with  biopsy  of  the  specimen  have  been  shown  to  have
 better  prediction  rate  of  T-staging  and  to  be  superior  to
US  studies.74,75
Retrospective  studies  comparing  surgery  to  endoscopic
herapy  for  early  neoplasms  have  shown  that  surgery  has
igher  short-term  mortality,76--80 whereas  endoscopy  has
ower  morbidity,  better  cost-effectiveness,81 and  a  lower
isk  of  complications.82,83
ndoscopic resection
MR  and  ESD  are  the  2  resection  procedures.  They  involve
 systematic  resection  of  a  speciﬁc  area  of  the  esopha-
us  with  an  endoscopic  knife  or  a  diathermy  snare.  They
re  used  especially  with  visible  nodular  dysplasia  and  short-
egment  dysplastic  BE,  for  which  they  are  preferred  over
he  ablative  techniques.  The  BSG  recommends  2  basic  tech-
iques  that  are  the  principle  behind  this  technique.  The
and  ligation  technique  involves  suction  of  the  desired  area
nd  deployment  of  a  band  that  creates  a  pseudo-polyp,
hich  can  be  removed  by  a  diathermy  snare.24 The  cap  and
nare  technique  involves  lifting  of  the  desired  area  with  a
ub-mucosal  injection  and  placing  a  cap  over  the  mucosa,
p
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hich  can  then  be  snared.24 EMR  for  HGD  and  EAC  T1a
tages  has  been  successful  in  91-98%  of  the  cases.84--86 More-
ver,  cohort  studies  have  shown  that  EMR  eradicates  BE  in
5-100%  of  patients  and  eradicates  dysplasia  in  86-100%  of
he  cases.87--92 Water  jet-assisted  ESD  has  been  attempted
ith  an  en-bloc  resection  rate  of  around  90%.93 Not  many
irect  studies  comparing  EMR  and  ESD  are  available,  but
he  study  by  Ishihara  et  al.  comparing  EMR  with  ESD  for
sophageal  squamous  cell  carcinoma  revealed  that  EMR  had
 higher  local  recurrence  rate  (23.91%  vs  3.13%),  suggest-
ng  that  ESD  is  the  preferred  technique  when  available,
ven  though  it  is  technically  more  demanding.94 Their  study
esults  also  suggest  that  despite  the  resection  of  the  dysplas-
ic  mucosa,  the  remaining  non-dysplastic  BE  is  still  at  risk
nd  hence  has  to  be  eradicated  by  further  resection  or  abla-
ion.  Wani  et  al.  reported  in  their  multicenter  cohort  study
hat  EMR  could  change  the  histological  diagnosis  in  up  to  30%
f  the  patients,  which  could  potentially  change  the  course  of
anagement.95 Complications  of  EMR  are  immediate  bleed-
ng  up  to  10%,76,85,96 perforation  in  3-7%  of  patients,83,86,97
nd  delayed  stricture  formation  in  17-37%  of  patients.98
ndoscopic ablative techniques
blative  techniques  can  be  thermal,  radiofrequency
blation  (RFA),  photodynamic  therapy  (PDT),  multipolar
lectro-coagulation  (MPEC),  cryotherapy,  and  argon  plasma
oagulation  (APC).  These  techniques  are  generally  per-
ormed  when  there  are  no  visible  lesions  in  the  dysplastic
pithelium,  in  which  case  resection  techniques  have  a  higher
uccess  rate.
PDT  involves  the  use  of  a photosensitive  chemical  like
-aminolevulinic  acid  or  porﬁmer  sodium  to  sensitize  the  tis-
ues  and  destroy  them  with  endoscopically  delivered  laser
ight.  The  laser  light  causes  free  radical  generation  upon
xposure  to  the  sensitized  cells,  thus  leading  to  damage.
uccess  rates  of  eradication  of  HGD  up  to  77%  in  5  years
ave  been  achieved.99,100 In  a retrospective  cohort  study  by
verholt  et  al.  involving  103  patients  presenting  with  BE
ith  dysplasia  and  IMC  that  had  a  mean  follow-up  of  50
onths,  intent-to-treat  success  and  eradication  rates  were
2.2%  for  low-grade  dysplasia,  77.5%  for  HGD,  and  44.4%  for
MC.99 Complications  included  stricture  formation  rates  up
o  30%,  photosensitivity  of  the  skin  in  up  to  33%  (p  <  0.05),
nd  buried  BE  epithelium  beneath  the  squamous  epithelium
hat  was  signiﬁcantly  higher  in  up  to  48%  of  patients  and  may
ventually  become  malignant.99--102 Pain  during  the  immedi-
te  post-operative  period  has  been  reported  as  a  signiﬁcant
ide  effect  in  most  of  the  patients,  with  studies  reporting
p  to  as  high  as  86%  of  patients.103,104 Due  to  comparatively
igher  complication  rates,  PDT  is  not  a  highly  favored  option
or  BE  therapy.
Cryoablation  therapy  is  a  non-contact  technique  that
nvolves  the  spraying  of  liquid  nitrogen  or  carbon  dioxide  to
reeze  and  destroy  the  Barrett’s  mucosa.105,106 Liquid  nitro-
en  or  carbon  dioxide  is  sprayed  to  freeze  the  tissue  for
0  to  20  s,  then  thawed  for  one  minute,  with  3-4  cycles
er  session.  Another  session  may  be  repeated  in  a  couple  of
onths  if  needed.  It  has  been  shown  to  cause  eradication  of
ntestinal  metaplasia  and  dysplasia  in  46-78%  and  79-87%  of
he  cases,  respectively.106,107 Dumot  et  al.  demonstrated  in
atme
m
e
w
g
7
p
I
w
t
f
a
i
A
i
t
m
R
e
t
r
a
h
r
r
r
q
p
d
r
u
o
t
tManagement  of  Barrett’s  esophagus:  Screening  to  newer  tre
their  non-randomized  cohort  trial  of  30  patients  that  68%  of
the  patients  with  HGD  and  80%  with  IMC  had  downstaging  of
HGD  or  elimination  of  cancer.108
MPEC  and  APC  are  other  endoscopic  eradication  tech-
niques  which  have  not  been  extensively  studied  for  the
treatment  of  BE,  although  there  are  several  prospective  case
series  that  describe  their  use  and  success.  Montes  et  al.
reported  an  eradication  rate  of  100%  of  cases  of  NDBE  in
his  series  with  14  patients  with  a  mean  follow-up  of  21.6
months,109 whereas  Sampliner  et  al.  reported  only  a 78%
eradication  rate  in  a  6-month  follow-up.110 For  APC,  Madisch
et  al.  reported  an  eradication  rate  of  98%  and  a  recur-
rence  rate  of  12%  in  his  series  with  a  mean  follow-up  of
51  months,111 whereas  another  study  reported  an  eradica-
tion  rate  of  only  84%  and  a  recurrence  rate  of  up  to  66%  in
a  follow-up  of  30  months.112 Randomized  controlled  studies
comparing  MPEC  with  APC  found  no  signiﬁcant  difference
between  eradication  rates,  but  both  needed  multiple  treat-
ment  sessions.
RFA  involves  an  assembly  of  closely  placed  electrodes  to
deliver  radiofrequency  energy  to  the  esophageal  mucosa,
thus  causing  ablation.  This  generates  uniform  thermal
energy  in  a  circumferential  fashion,  while  the  power,  dura-
tion,  and  density  of  thermal  energy  can  be  varied.  Several
studies  have  compared  RFA  with  other  ablative  therapies
and  have  shown  that  RFA  has  a  better  success  rate,  a
lower  recurrence  rate  of  dysplasia,  and  is  comparatively
safer  than  other  techniques.  A  prospective  multicenter
study  demonstrated  a  70%  remission  in  BE  in  circumferential
treatment,113 but  Ganz  et  al.  published  a  subsequent  report
that  described  a  98%  eradication  rate  when  a  focal  abla-
tion  technique  was  used  after  circumferential  ablation.114
In  a  multi-center  sham-controlled  trial  with  127  patients
with  dysplastic  BE,  there  was  complete  eradication  of  LGD  in
90.5%  (p  <  0.001)  of  the  patients  and  in  81%  of  the  patients
with  HGD  (p  <  0.001)  during  a  12-month  follow-up.115 In  a
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Recurrence rates and eradication rates of high-gra
Barrett’s esophagus with various endoscopic eradic
Study  Year  Endoscopic
eradication
technique
Number  of
patients
Overholt  et  al.100 2003  PDT  65  
Dunn et  al.101 2013  ALA,
Photofrin-PDT
64  
Dumot et  al.108 2009  Cryotherapy  30  
Shaheen et  al.106 2010  Cryotherapy  60  
Halsey et  al.122 2011  Cryotherapy  36  
Shaheen et  al.115 2009  RFA  127  nts  97
ulticenter,  randomized,  controlled  trial  conducted  by  Phoa
t  al.,  comparing  RFA  with  endoscopic  surveillance  for  BE
ith  LGD,  it  was  shown  that  RFA  reduced  the  risk  of  pro-
ression  to  HGD  by  25%  (p  <  0.001)  and  adenocarcinoma  by
.6%  (p  =  0.03)  during  a  3-year  follow-up.116 There  was  com-
lete  resolution  of  the  dysplasia  in  92.6%  of  the  patients.
n  a  United  Kingdom-based  registry  involving  335  patients
ith  BE,  with  72%  of  them  having  HGD,  RFA  ablation  led
o  86%  resolution  and  clearance  of  HGD  during  a  12-month
ollow-up.117 Shorter  segment  Barrett’s  responded  better
nd  reversal  of  dysplasia  was  15%  less  likely  with  every
ncremented  centimeter  in  the  length  of  the  BE  segment.117
 systematic  review  comparing  sub-squamous  metaplasia
n  RFA  and  PDT-treated  patients  showed  that  0.9%  of  RFA-
reated  patients  and  14.2%  of  PDT-treated  patients  had
etaplasia,  thus  demonstrating  the  superior  efﬁcacy  of
FA.118 In  a  systematic  review  and  meta-analysis  by  Orman
t  al.,  the  most  frequent  complication  was  stricture  forma-
ion  (5%),  followed  by  pain  (3%)  and  bleeding  (1%),  which
eﬂects  the  results  in  most  of  the  other  published  articles
nd  retrospective  studies.119 RFA  has  also  been  shown  to
ave  a  lower  stenosis  rate  than  stepwise  radical  endoscopic
esection  (14%  vs  88%,  p  <  0.001).120 Despite  the  positive
esults  of  ablation  procedures  in  eliminating  dysplasia  and
educing  neoplastic  progression,  their  role  in  NDBE  has  been
uestioned  by  studies  in  relation  to  the  recurrence  of  meta-
lasia  during  follow-up  due  to  sub-squamous  metaplasia,
urability  of  response,  and  in  some  analyses,  a  recurrence
ate  up  to  33%.121 Hence,  ablation  procedures  might  be  a
seful  approach  in  LGD  treatment,  given  the  reduced  rate
f  progression  to  cancer.  However,  the  unnecessary  subjec-
ion  of  NDBE  patients  to  these  endoscopic  procedures  with
he  consequent  increase  in  complication  rates  demand  the
ublication  of  long-term  data.  Under  the  present  circum-
tances,  ablation  procedures  are  not  recommended  by  the
edical  societies.
de dysplasia and intra-mucosal cancer in
ation techniques
Mean  length  of
follow-up
(months)
Rate  of
recurrence  (%)
Rate  of
eradication  (%)
58.5  4.9  NA
24  14  ALA  47
Photofrin  40
12  NR  HGD  68,
IMC  80
10.5  3  HGD  97,
dysplasia  87,
metaplasia  57
24  Dysplasia  17
Metaplasia  30
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haheen  et  al.123 2011  RFA  54  36  24  months:
dysplasia  93,
metaplasia  89
36  months:
dysplasia  98,
metaplasia  91
an Vilsteren
et  al.120
2011  EMR  +  RFA  vs
SRER
47  24  0.02  EMR  +  RFA:
HGD  96,
IMC  96
SRER:
HGD  100,
IMC  92
upta et  al.121 2013  RFA,  EMR  448  24  33  56
ay A  et  al., 85 2002  EMR,  PDT  115  34  30%
metachronous
lesions
98%  local
remission
eewald et  al.91 2003  EMR  12  9  0  100
ech O  et  al.124 2003  EMR  550  12  NA  82.5
onio et  al., 87 2005  EMR  39  34.9  NA  100
arghi et  al.89 2007  EMR  26  28  12.5  87.5
opes et  al.90 2007  EMR  41  31.6  24.4  75.6
ech O  et  al.86 2008  EMR/  PDT  349  63.6  21.5%
metachronous
lesions
96.6
oss A  et  al.75 2010  EMR  75  7  11%
metachronous
lesions
94
LA: 5-Aminolevulinic acid; EMR: Endoscopic mucosal resection; HGD: High-grade dysplasia; IMC: Intra-mucosal carcinoma; NA: Not addressed
DT: Photodynamic therapy; RFA: Radiofrequency ablation; SRER: Stepwise radical endoscopic resection.
urgical management
or  several  decades,  esophagectomy  was  the  traditional
reatment  option  for  HGD.  It  eliminates  both  dysplastic
nd  non-dysplastic  BE,  providing  a  tissue  sample  for  biopsy
nd  also  allowing  removal  of  lymph  nodes  with  metasta-
is.  Surgical  therapy  is  considered  the  treatment  of  choice
hen  there  is  sub-mucosal  invasion  with  an  increased  risk
f  metastasis.  There  are  several  esophagectomy  techniques
nd  they  have  shown  similar  outcomes.  Transhiatal,  tho-
acoabdominal,  vagal-sparing,  Merendino  segmental,  and
inimally  invasive  laparoscopic  or  thoracoscopic  esophagec-
omy  options  are  practiced.24 When  compared  with  the
ndoscopic  therapies,  they  have  a  signiﬁcantly  higher  rate
f  mortality  and  morbidity,  especially  short-term,  but  with
lmost  similar  survival  rates.80 Most  of  the  studies  have  been
one  on  symptomatic,  old,  and  debilitated  patients  who  had
 higher  rate  of  mortality  than  the  smaller  series  in  younger
opulations  that  had  a  mortality  of  less  than  3.3%.79 It  has
lso  been  shown  to  affect  the  quality  of  life  in  the  short
erm  while  long-term  studies  have  demonstrated  results
omparable  to  those  in  the  general  population.  Rare  occur-
ences  of  neo-metaplasia  in  the  esophageal  remnant  due
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